Pink SheetDespite the “chaotic” early days, experts said plenty of opportunities are available to work with President Donald Trump’s new administration, although the biopharma industry must frame lobbying effor
Pink SheetUpcoming negotiations to reauthorize the US Food and Drug Administration’s prescription drug user fee program should be viewed as a chance to make the program more efficient in the face of an administ
ScripAdvice For Working With Trump The biotech industry is only about one month into working with a new administration in the US following the inauguration of Donald Trump as president – and the pace of
In Vivo“How does it feel that you have a billion-dollar neuroscience commercial business, and no one cares?” That’s the question an investor asked Alkermes’ chief operating officer Blair Jackson at the recen